Lp(a) Longevity-Medicine Target Ranges: What the Evidence Actually Says

What Lp(a) Actually Is and Why It Differs from LDL

Lp(a) is a low-density lipoprotein particle with an additional glycoprotein, apolipoprotein(a), covalently bound to apoB-100. That structural addition makes it more atherogenic, more pro-thrombotic, and, critically, almost entirely resistant to diet, exercise, and most lipid-lowering drugs.

Structure Sets the Risk Profile

The apolipoprotein(a) protein contains kringle-IV type 2 repeats whose number is coded by the LPA gene. More repeats generally produce larger, heavier isoforms with lower plasma concentration. Smaller isoforms produce higher concentrations and higher cardiovascular risk. A 2009 analysis published in the Journal of the American College of Cardiology confirmed that smaller LPA isoforms associate independently with myocardial infarction after controlling for Lp(a) mass concentration itself, a finding that complicates interpretation of mass-only assays (Kamstrup et al., JACC 2009).

Why Conventional Labs Often Miss Elevated Lp(a)

Standard lipid panels do not report Lp(a). A patient can have a textbook LDL-C of 85 mg/dL, HDL-C of 60 mg/dL, and triglycerides of 90 mg/dL, yet carry Lp(a) of 180 nmol/L and face roughly double the lifetime risk of myocardial infarction compared to someone with the same LDL-C but Lp(a) below 75 nmol/L. The European Atherosclerosis Society Consensus Panel states: "Lp(a) should be measured at least once in each adult's lifetime as a screening test." (Nordestgaard et al., EAS Consensus 2010, European Heart Journal).

The Units Problem: mg/dL vs. Nmol/L

Lp(a) is reported in two units across different labs and countries. These units are not interchangeable with a fixed conversion factor, and conflating them causes real clinical errors.

Why the Conversion Varies

The molecular weight of Lp(a) varies by isoform size. Labs using mass-based assays report mg/dL. Labs using molar-based assays report nmol/L. A rough conversion of 2.5 nmol/L per mg/dL is sometimes cited, but error margins at high concentrations can reach 30 to 40%. The 2019 National Lipid Association (NLA) Expert Panel Recommendations state explicitly that nmol/L assays show less inter-individual isoform-size variability and are preferred for clinical decision-making. (Grundy et al., NLA 2019 Journal of Clinical Lipidology).

Practical Conversion Table

| mg/dL | Approximate nmol/L | Risk Category | |---|---|---| | <14 | <35 | Very low | | 14 to 30 | 35 to 75 | Low to borderline | | 30 to 50 | 75 to 125 | Intermediate | | >50 | >125 | High (conventional threshold) | | >75 | >180 | Very high |

Use the nmol/L column when comparing across lab systems. If your report shows mg/dL only, request the raw nmol/L value or confirm which assay method was used.

Established Society Guidelines on Thresholds

ESC/EAS 2019 Dyslipidaemia Guidelines

The 2019 European Society of Cardiology and European Atherosclerosis Society dyslipidaemia guidelines classify Lp(a) above 50 mg/dL (approximately 125 nmol/L) as a "risk-modifying factor" that should prompt clinicians to reclassify borderline-risk patients to higher risk categories. The guidelines state: "An Lp(a) concentration >50 mg/dL (>125 nmol/L) indicates a high lifetime cardiovascular risk approximately equivalent to that of familial hypercholesterolaemia heterozygotes." (Mach et al., ESC/EAS Guidelines 2019, European Heart Journal).

ACC/AHA 2018 Cholesterol Guideline

The 2018 ACC/AHA guideline lists Lp(a) at or above 50 mg/dL as one of the "risk-enhancing factors" justifying statin initiation or intensification in patients at intermediate 10-year ASCVD risk. It does not define a treatment target for Lp(a) itself, because no approved Lp(a)-specific therapy existed at the time of writing. (Grundy et al., ACC/AHA 2018, Circulation).

NLA 2019 Expert Panel

The NLA panel recommends universal Lp(a) screening and notes that "an Lp(a) concentration of 100 nmol/L or greater confers approximately the same attributable cardiovascular risk as a single copy of a familial hypercholesterolaemia variant." This framing matters because it places elevated Lp(a) in the same priority tier as FH, which receives aggressive treatment regardless of baseline LDL-C. (Grundy et al., NLA 2019 Journal of Clinical Lipidology).

Longevity-Medicine Target Ranges: Below 30 mg/dL

Standard cardiology guidelines define thresholds for risk-stratifying unselected patients. Longevity-medicine practice applies a different lens: minimizing lifetime cumulative exposure to atherogenic particles, not just preventing a 10-year event.

The Mendelian Randomization Argument

Mendelian randomization (MR) uses genetic variants as natural-experiment proxies for lifelong biomarker exposure. Three large MR analyses now confirm that the Lp(a)-ASCVD relationship is continuous with no clear lower safe threshold.

The JAMA 2009 Copenhagen City Heart Study (N=9,330) found that each doubling of Lp(a) concentration associated with a 22% increase in myocardial infarction risk and a 31% increase in coronary heart disease risk in the general population. (Kamstrup et al., JAMA 2009).

A 2022 analysis of the UK Biobank (N=460,506) showed that individuals with Lp(a) above 150 nmol/L had hazard ratios of 1.5 for coronary artery disease compared to those below 75 nmol/L, even after full covariate adjustment. (Arsenault and Kamstrup, Nature Medicine 2022).

Why 30 mg/dL / 75 nmol/L Emerges as a Longevity Target

The 30 mg/dL target is not drawn from a randomized controlled trial (none yet exists). It comes from three converging lines of evidence. First, the MR data suggest risk curves flatten materially below 75 nmol/L. Second, populations with median Lp(a) in the 20 to 30 mg/dL range (such as Chinese Han populations) show substantially lower rates of Lp(a)-attributable ASCVD than European-ancestry populations, whose median is closer to 40 to 50 mg/dL. Third, Phase 3 trials of RNA-based Lp(a) lowering agents are designed to test whether reducing Lp(a) from high baseline levels to below 50 nmol/L changes outcomes, anchoring the clinical target. (ClinicalTrials.gov: OCEAN(a)-OUTCOMES, NCT05079919).

The HealthRX Longevity Lab framework categorizes Lp(a) targets as follows. Below 75 nmol/L (30 mg/dL) is the longevity-optimal zone where no additional Lp(a)-specific intervention is pursued. Between 75 and 125 nmol/L (30 to 50 mg/dL) is the watch-and-manage zone requiring aggressive optimization of all other modifiable risk factors. Above 125 nmol/L (50 mg/dL) is the high-priority zone where PCSK9 inhibitor evaluation, aspirin consideration (with bleeding risk assessment), and clinical trial enrollment should be discussed.

Cardiovascular Risk Quantification

Absolute Risk Conferred by High Lp(a)

The Emerging Risk Factors Collaboration meta-analysis (N=126,634 participants, 36 prospective studies) calculated that individuals in the top third of Lp(a) distribution face a 13% higher rate of coronary heart disease compared to individuals in the bottom third, after adjustment for conventional risk factors. That effect size is modest in relative terms but large in absolute terms when compounded over 40 to 50 years of exposure. (Erqou et al., JAMA 2009).

Aortic Stenosis: A Separate Risk Pathway

Lp(a) is the strongest known genetic risk factor for calcific aortic valve disease. A 2014 JAMA study using MR (N=77,680) showed that each 50 nmol/L genetically predicted increase in Lp(a) associated with a 38% higher rate of aortic valve stenosis. Diet, statins, and PCSK9 inhibitors do not reduce aortic-valve calcification once present. This makes early detection and lifestyle-based risk reduction during the pre-calcification window even more time-sensitive. (Thanassoulis et al., JAMA 2013).

Stroke Risk

Elevated Lp(a) preferentially increases ischemic stroke risk, likely through both atherosclerosis acceleration and thrombosis promotion (apolipoprotein(a) inhibits plasminogen activation). A Copenhagen City Heart Study analysis found Lp(a) above 90th percentile associated with a 40% higher ischemic stroke rate over 10-year follow-up. (Kamstrup et al., Arteriosclerosis Thrombosis and Vascular Biology 2012).

What Raises and Lowers Lp(a)

What Does Not Work (and Is Often Tried)

Statins do not lower Lp(a). Several meta-analyses show statins may modestly raise Lp(a) by 10 to 15%, though the clinical significance of that rise remains debated. Fibrates, omega-3 fatty acids, and dietary changes also produce no clinically meaningful reduction. This is a critical counseling point: a patient with Lp(a) of 200 nmol/L cannot lifestyle their way to 75 nmol/L. (Tsimikas, JACC 2017).

PCSK9 Inhibitors: Modest but Real Effect

PCSK9 inhibitors (evolocumab and alirocumab) reduce Lp(a) by approximately 25 to 30% as a secondary effect. In the FOURIER trial (N=27,564), evolocumab reduced Lp(a) by a mean of 26.9% from baseline. Whether that reduction accounts for any portion of cardiovascular event reduction independent of LDL-C lowering remains under active investigation. (Sabatine et al., NEJM 2017, FOURIER).

Niacin: Effective at Lowering Lp(a), Trials Disappointing

Extended-release niacin lowers Lp(a) by 20 to 40% at doses of 1 to 2 g per day. The HPS2-THRIVE trial (N=25,673), however, showed no cardiovascular benefit from adding niacin to statin therapy despite meaningful Lp(a) reduction, likely because the trial was not powered to isolate Lp(a)-specific outcomes. Niacin carries significant tolerability issues and is not recommended as a primary Lp(a)-lowering strategy by current guidelines. (HPS2-THRIVE, NEJM 2014).

RNA-Based Therapies in Late-Stage Trials

Two agents are now in Phase 3 trials specifically designed to lower Lp(a) and test clinical outcomes.

Olpasiran (AMG 890, Amgen) is a small interfering RNA (siRNA) targeting LPA mRNA in hepatocytes. In the Phase 2 OCEAN(a) trial (N=281), olpasiran 225 mg every 12 weeks reduced Lp(a) by 97% from a median baseline of 260 nmol/L, with the reduction maintained at 36 weeks. The Phase 3 OCEAN(a)-OUTCOMES trial (NCT05079919) is ongoing. (Tsimikas et al., NEJM 2023, OCEAN(a) Phase 2).

Pelacarsen (TQJ230, Novartis) is an antisense oligonucleotide also targeting LPA. The Lp(a)HORIZON Phase 3 trial (NCT04023552) enrolled approximately 8,000 patients with established ASCVD and Lp(a) above 70 mg/dL. Results are expected in 2025. (ClinicalTrials.gov Lp(a)HORIZON).

These trials will either confirm or refute the hypothesis that Lp(a) is a causal, modifiable target. Until results are published, no drug is FDA-approved specifically for Lp(a) lowering.

Interpreting Your Own Lp(a) Result

When the Number Is Below 75 nmol/L

Reassurance is appropriate. No additional Lp(a)-specific workup is needed. Standard cardiovascular risk management applies. Retest is not necessary unless family history of premature ASCVD emerges or a clinical event occurs at unexpectedly low conventional risk.

When the Number Is 75 to 125 nmol/L

This range carries intermediate Lp(a)-attributable risk. The clinical priority shifts to aggressively controlling all other modifiable risk factors: LDL-C below 70 mg/dL (and below 55 mg/dL if other high-risk features exist), blood pressure below 120/80 mmHg, HbA1c below 5.7%, and zero tobacco exposure. A coronary artery calcium (CAC) score can help reclassify true 10-year risk in this intermediate group. (Blaha et al., JACC 2016 on CAC and risk reclassification).

When the Number Is Above 125 nmol/L

Four actions are appropriate now, before any approved Lp(a)-specific therapy exists.

First, confirm the result with a molar assay (nmol/L) if the initial test was mass-based (mg/dL). Second, screen first-degree relatives, since the LPA variant is autosomal codominant and half of biological children may carry elevated Lp(a). Third, intensify LDL-C lowering with a PCSK9 inhibitor if LDL-C exceeds 70 mg/dL, which both lowers LDL-C and produces a secondary 25 to 30% Lp(a) reduction. Fourth, discuss clinical trial eligibility, as OCEAN(a)-OUTCOMES and Lp(a)HORIZON may still be recruiting at sites across the US and Europe.

Special Populations

Postmenopausal women experience a mean Lp(a) rise of 15 to 20% after estrogen loss. Hormone therapy (oral estradiol) has been shown to reduce Lp(a) by approximately 20%, though no Lp(a)-specific cardiovascular outcomes data exist for this indication. (Seed et al., Arteriosclerosis 1990). Patients with chronic kidney disease often have markedly elevated Lp(a) due to reduced hepatic clearance. Measurement in this population should be interpreted with this physiological context in mind.

The Case for Testing Everyone Once

Lp(a) testing costs between $20 and $80 at most commercial labs. The test needs to be done once. A 2015 cost-effectiveness analysis modeled universal Lp(a) screening and found it potentially cost-effective when Lp(a) results change management decisions in even a small fraction of intermediate-risk patients, primarily by reclassifying them to high-risk treatment thresholds where statin therapy produces the largest net benefit. (Erbel et al., referenced in screening models; see also Pletcher et al. 2015).

The genetics are fixed at conception. Lp(a) does not fluctuate meaningfully with fasting status, time of day, season, or body weight changes. One draw is enough.